These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 25448549)

  • 21. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.
    Khare V; Kour S; Alam N; Dubey RD; Saneja A; Koul M; Gupta AP; Singh D; Singh SK; Saxena AK; Gupta PN
    Int J Pharm; 2014 Aug; 470(1-2):51-62. PubMed ID: 24810239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
    Pili B; Reddy LH; Bourgaux C; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
    Nanoscale; 2010 Aug; 2(8):1521-6. PubMed ID: 20820745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S; Bigand C; Parmentier C; Hajri A
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice.
    Smith RC; Bulanadi JC; Gill AJ; Rye KA; Hugh T; Proschogo N; Smith SF; Phillips L; Gong X; Julovi SM; Xue A; Moghaddam MJ
    Cancer Lett; 2020 Dec; 495():112-122. PubMed ID: 32949679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy.
    Bui DT; Nicolas J; Maksimenko A; Desmaële D; Couvreur P
    Chem Commun (Camb); 2014 May; 50(40):5336-8. PubMed ID: 24185552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revealing the impact of modified modules flexibility on gemcitabine prodrug nanoassemblies for effective cancer therapy.
    Guo J; Zhang X; Dong F; Wang S; Wang D; Li Y; Zuo S; Wang Q; Li W; Sun J; He Z; Zhang T; Jiang Q; Sun B
    J Colloid Interface Sci; 2025 Jan; 677(Pt A):941-952. PubMed ID: 39128288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy.
    Maksimenko A; Alami M; Zouhiri F; Brion JD; Pruvost A; Mougin J; Hamze A; Boissenot T; Provot O; Desmaële D; Couvreur P
    ACS Nano; 2014 Mar; 8(3):2018-32. PubMed ID: 24555414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
    Wu W; Sigmond J; Peters GJ; Borch RF
    J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
    Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
    Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice.
    Rodríguez-Nogales C; Mura S; Couvreur P; Blanco-Prieto MJ
    Int J Pharm; 2020 May; 582():119345. PubMed ID: 32311470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
    Arias JL; Reddy LH; Othman M; Gillet B; Desmaële D; Zouhiri F; Dosio F; Gref R; Couvreur P
    ACS Nano; 2011 Feb; 5(2):1513-21. PubMed ID: 21275408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
    Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
    J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine.
    Reddy LH; Marque PE; Dubernet C; Mouelhi SL; Desmaële D; Couvreur P
    J Pharmacol Exp Ther; 2008 May; 325(2):484-90. PubMed ID: 18258784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer cell membrane-modified Soluplus® micelles for gemcitabine delivery to pancreatic cancer using a prodrug approach.
    Pereira-Silva M; Diaz-Gomez L; Blanco-Fernandez B; Ferreirós A; Veiga F; Concheiro A; Paiva-Santos AC; Alvarez-Lorenzo C
    Int J Pharm; 2024 Sep; 662():124529. PubMed ID: 39084580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
    Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
    Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
    Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
    Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
    Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.